Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

1. A method of treating a myeloproliferative disorder in a patient in need thereof, comprising administering to the patient a compound selected from:

3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(1,2-dihydroxycyclopentyl)propanenitrile, or a pharmaceutically acceptable salt thereof; and

3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(1-hydroxycyclopentyl)propanenitrile, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the myeloproliferative disorder is polycythemia vera (PV).

3. The method of claim 1 , wherein the myeloproliferative disorder is essential thrombocythemia (ET).

4. The method of claim 1 , wherein the myeloproliferative disorder is myeloid metaplasia with myelofibrosis (MMM).

5. The method claim 1 , wherein said compound is 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(1,2-dihydroxycyclopentyl)propanenitrile.

6. The method of claim 1 , wherein said compound is 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(1-hydroxycyclopentyl)propanenitrile.